Apollo Hospitals Chennai performs India’s first adaptive deep brain stimulation for Parkinson’s

Milestone marks a major leap toward real-time, personalised neuromodulation therapy as India’s Parkinson’s burden rises sharply

Beacon raises $132M+ to bring AI-driven sleep diagnostics to masses

The device aims to bring precision neuroscience into clinical trials, accelerating drug development

Lupin Foundation expands NCD care access in Rajasthan with new diagnostic corners

The initiative is aimed at strengthening the district-level screening and chronic disease management infrastructure

Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9 billion

The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio

Alpha Cognition secures key US patent for traumatic brain injury treatment

The patent, titled “ALPHA-1062 for treating Traumatic Brain Injury,” strengthens Alpha Cognition’s existing portfolio supporting both ALPHA-1062 and ZUNVEYL

WHO updates global guidelines to combat opioid crisis

Opioid dependence remains a major driver of death and disease worldwide

KIMS Hospitals launches cutting-edge Neurosciences Institute in Mahadevapura

HRV Pharma, Shodhana join hands to build next-gen API pipeline for global markets

Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets

Enveric Biosciences bags key US patent for mental health drug

EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes

Experts advocate holistic Semaglutide use as therapy goes off patent in India

They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market